Obsessive Compulsive Disorder Ocd

Boston, MA

64 Obsessive Compulsive Disorder Ocd Trials near Boston, MA

Power is an online platform that helps thousands of Obsessive Compulsive Disorder Ocd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Psilocybin for Depression

New Haven, Connecticut
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. A DSM-5 diagnosis is not required (nor is it an exclusion). The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions. The investigators will employ an open-label study where participants will be given one dose of oral psilocybin 25mg. The investigators will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

50 Participants Needed

Family Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder

Vancouver, British Columbia
Obsessive-Compulsive Disorder (OCD) is a common neuropsychiatric illness beginning in childhood. Effective OCD treatments include cognitive-behaviour therapy (CBT) and medications but access to treatment is difficult and does not systematically include parents. The investigators will evaluate clinical and neural effects of Group-based Family CBT (GF-CBT), via a case-control study including: Group 1 - OCD cases receiving GF-CBT (N=90); Group 2 - OCD waitlist cases (N=90). Effects will be measured between baseline and completion of 12 GF-CBT sessions: comparing OCD severity and functioning changes between Groups 1 and 2.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 18

180 Participants Needed

Exposure and Response Prevention for Obsessive-Compulsive Disorder

Northport, New York
This trial will test a therapy called ERP, which helps people face their fears and stop doing habits that make them feel temporarily better but keep the problem going. It will focus on Veterans with OCD, including those who also have PTSD. The goal is to see if this therapy improves their daily functioning and quality of life.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

160 Participants Needed

Celecoxib for Obsessive-Compulsive Disorder

New York, New York
This trial tests if adding the anti-inflammatory drug celecoxib to current treatments helps adults with OCD who still have symptoms. It focuses on patients with high brain inflammation, measured by scans and blood tests, to see if they improve more with this added medication. Celecoxib has been tested as an additional therapy in schizophrenia, showing significant improvement in symptoms, particularly in patients with recent-onset schizophrenia.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55

21 Participants Needed

rTMS for Obsessive-Compulsive Disorder

New York, New York
The goal of this clinical trial is to discover brain-based subtypes of Obsessive Compulsive Disorder (OCD) and examine treatment response to two different repetitive transcranial magnetic stimulation (rTMS) targets in the brain: the medial prefrontal cortex (MPFC) and the right prefrontal cortex (rPFC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

360 Participants Needed

DBS Therapy for Obsessive-Compulsive Disorder

Queens, New York
This trial involves using Deep Brain Stimulation (DBS) to help patients with severe OCD who haven't responded to other treatments. The DBS device sends electrical signals to specific brain areas to control OCD symptoms by regulating abnormal brain activity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

50 Participants Needed

Cognitive Control Training for Obsessive-Compulsive Disorder

New York, New York
This study aims to examine the effects of a game-like program called cognitive control training (CT) for children with obsessive compulsive disorder (OCD). Children enrolled in this study will receive 4 weeks of the at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games to engage cognitive control processes. Children will complete the NIH Toolbox prior to, mid (2-weeks), and post-CT (4-weeks). Participants will complete MRI scans pre- and post-CT and then be offered a 12-week course of gold-standard Cognitive behavioral therapy with exposure and response prevention (or community referrals) after CT. The long-term goal of this study is to test how this CT intervention may enhance cognitive control capacity to reduce symptoms and improve response to cognitive behavioral therapy with exposure and response prevention in children with OCD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 12

60 Participants Needed

Accelerated TMS for Depression and OCD

New York, New York
This trial tests a new, faster treatment for people with depression and OCD. The goal is to see if this approach can quickly improve symptoms. The study also uses brain scans to find markers that predict who will benefit most from the treatment. This method has shown effectiveness in treating depression and cognitive impairment, and is being explored for its potential in treating OCD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

500 Participants Needed

Deep Brain Stimulation for Obsessive-Compulsive Disorder

New York, New York
This trial uses a technique called deep brain stimulation (DBS) to help people with severe OCD who haven't improved with other treatments. Electrodes are placed in a specific brain area to send electrical impulses that adjust brain activity and reduce symptoms. The study aims to personalize the stimulation for each patient to maximize benefits.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

20 Participants Needed

Exposure and Response Prevention for Obsessive-Compulsive Disorder

New York, New York
This trial studies how hormonal changes during the menstrual cycle affect the effectiveness of a common OCD therapy called Exposure and Response Prevention (EX/RP). Women will undergo therapy at various points in their cycle, and men will also participate for comparison. The goal is to see if timing therapy with hormonal changes can improve outcomes for women with OCD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

120 Participants Needed

Exposure and Response Prevention for OCD

New York, New York
Psychiatric disorders characterized by compulsivity, such as obsessive-compulsive disorder (OCD), result in considerable functional impairment and many individuals do not respond to gold-standard treatments. Compulsivity has long been thought to occur due to exaggerated habits and reduced goal-directed control, although more recently, this conceptualization of compulsivity as an imbalance of two cognitive systems has been challenged as overly narrow. This study will recruit 100 individuals (50 adults diagnosed with OCD, 50 healthy controls) and leverage the measurement precision offered by theory-driven computational modeling in combination with electroencephalogram (EEG) to go beyond this binary theory of compulsivity, revealing how more complex interactions of neurocognitive subcomponents contribute to compulsivity-information that could ultimately lead to improved treatment personalization and clinical outcomes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55

100 Participants Needed

Psychotherapy for Obsessive-Compulsive Disorder

Montreal, Quebec
Obsessive-compulsive disorder (OCD) is a disabling psychiatric illness that is characterized by distressing obsessional thoughts and time-consuming compulsive rituals. Exposure and Response Prevention (ERP) is a first-line psychological treatment of choice that requires patients to face their fears by being exposed to feared stimuli. This treatment has been shown to reduce symptoms in a significant proportion of patients. However, it is considered a difficult treatment and only a minority reach remission. Residual symptoms typically remain, or reappear after treatment, which is a risk for relapse. Inference-based Cognitive Behavioral Therapy (I-CBT) is a promising evidence-based treatment developed to overcome these limitations. I-CBT has already been found to be as effective as ERP and significantly more acceptable and easier to adhere to. There is also evidence that I-CBT is more effective for subgroups of patients. Consequently, the current research project is focused on improving treatments outcomes for those provide those who have previously unable to reach remission of their symptoms with ERP. Following an initial treatment with ERP, those that have been unable to reach remission, will be randomized to either I-CBT or more ERP. It is expected that I-CBT will be significantly more effective than providing patients with more of the same. In addition, the study aims to predict treatment outcome in order to be able to tell in advance which patients do not respond to ERP. The project is designed to maximize beneficial health outcomes with a stepped-care approach to treatment, but also to work towards a more personalized choice by being able to match patients in advance with the treatment that works best for them
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

160 Participants Needed

Cognitive Therapy vs Exposure Therapy for OCD

Montréal-Est, Quebec
Obsessive-compulsive disorder (OCD) is a highly disabling psychiatric illness, characterized by obsessional thoughts that cause patients to perform time-consuming and distressing compulsive rituals. Exposure and Response Prevention (ERP) is a first-line psychological treatment of choice, which requires patients to face their fears by being exposed to feared stimuli. ERP has been shown to reduce symptoms among those who comply with treatment. However, there is still a significant portion of patients that do not improve, especially those who firmly believe their obsessions are realistic and reasonable (i.e. OCD with Overvalued Ideation (OVI)). Also, a signficant proportion of patients refuse the treatment or drop out during treatment due to the distress provoked by ERP. Even among those that do improve, residual symptoms often remain, or symptoms may reappear after treatment. One evidence-based approach to the treatment of OCD, termed inference-based cognitive therapy (IBCT) has been shown to be as effective as ERP with the potential to overcome some of the limitations of ERP. Since IBCT is a cognitive approach, the treatment does not require exposure to feared stimuli and likely more tolerable for patients with OCD. Also, there is evidence that IBCT is more effective than ERP for those with overvalued ideation, since it directly targets the distorted reasoning that is responsible for the intensity and persistence of the obsession. The current study aims to directly compare ERP with this promising evidence-based cognitive therapy, which is expected to be significantly more effective for those with overvalued ideation, as well as significantly more tolerable with lower rates of treatment refusal, drop-out and higher treatment satisfaction. The project is designed to maximize potential beneficial health outcomes and offer a new evidence-based treatment option for the large proportion of patients unable to benefit from ERP.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

150 Participants Needed

Deep Brain Stimulation for Obsessive-Compulsive Disorder

Philadelphia, Pennsylvania
This trial tests a device that sends electrical signals to the brain in patients with severe OCD who don't respond to usual treatments. The electrical pulses aim to help control OCD symptoms. This experimental treatment has shown promising results for severe OCD.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 75

10 Participants Needed

Freespira Breathing System for Anxiety

Baltimore, Maryland
This study will test the efficiency of the Freespira Breathing System in youth.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:9 - 17

73 Participants Needed

Psilocybin for OCD

Baltimore, Maryland
This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:21 - 80

30 Participants Needed

Personalized Assessments for Childhood OCD

Baltimore, Maryland
The primary purpose of this study is to learn whether personalized assessment of obsessive-compulsive disorder (OCD) symptoms in childhood OCD using mobile health technology are feasible and acceptable for youth and parents. The investigators will also examine whether personalized cognitive-behavioral therapy (CBT) that is informed by personalized OCD assessments yields better clinical outcomes when compared to standard CBT for youth with OCD
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 17

30 Participants Needed

rTMS + Cognitive Behavioural Therapy for Obsessive-Compulsive Disorder

Toronto, Ontario
Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard first-line treatment for obsessive-compulsive disorder (OCD). Because CBT is a psychological treatment that aims to change patterns of thinking and behaving, it may be that improvement in cognitive functioning before treatment starts could lead CBT to be even more effective. One area of research that has shown potential benefit for OCD sufferers is rTMS. rTMS is a non-invasive procedure that uses pulses of energy to stimulate regions of the brain. Brief treatment with rTMS has shown to improve attention, memory, and other aspects of cognitive functioning that may facilitate learning in CBT. The proposed study aims to provide a pilot test of the clinical effectiveness of adding brief rTMS prior to completing CBT for OCD. If rTMS can demonstrate enhancement of cognitive functioning, which in turn, can improve treatment response to CBT, then the findings could easily be translated into routine clinical care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

10 Participants Needed

rTMS for Obsessive-Compulsive Disorder

Toronto, Ontario
This trial aims to obtain initial evidence about the clinical efficacy and modulation of neurophysiological markers in obsessive compulsive disorder (OCD) using personalized (i.e., electroencephalography (EEG)-triggered) repetitive transcranial magnetic stimulation (rTMS) as compared to non-personalized (i.e., non-EEG triggered), standard rTMS applied to the dorsomedial prefrontal cortex.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

48 Participants Needed

Psilocybin for OCD

Toronto, Ontario
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

10 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

Mindfulness-Based Interventions for Obsessive-Compulsive Disorder

Toronto, Ontario
This trial is testing a new treatment called Mindfulness-Based Cognitive Therapy (MBCT) for people with Obsessive-Compulsive Disorder (OCD) who haven't fully benefited from standard treatments. MBCT helps patients become more aware of their thoughts and feelings without reacting to them, which can reduce OCD symptoms. If successful, this approach could be used widely in clinical settings to help more people with OCD. Mindfulness-Based Cognitive Therapy (MBCT) has been shown to be effective in various mental disorders and is now being explored as a complementary treatment for OCD, particularly for those who do not fully benefit from standard treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

420 Participants Needed

Transcranial Magnetic Stimulation + Habit Training for Compulsive Behavior

Pittsburgh, Pennsylvania
This trial uses a device that sends mild electrical signals to the brain and combines it with computer exercises. It aims to help people who have trouble controlling repetitive behaviors. The goal is to change brain activity and improve control over these behaviors.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

200 Participants Needed

Neurostimulation + Therapy for Emotional Regulation Issues

Durham, North Carolina
This trial tests a new method that combines teaching emotion management skills with a type of brain stimulation. The goal is to help adults who struggle to calm down when upset and have certain mental health conditions. The brain stimulation aims to make it easier for them to learn and use these skills effectively.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55

240 Participants Needed

tDCS for Obsessive-Compulsive Disorder

Lexington, Kentucky
The goal of this study is to find out if brain stimulation can help people stop skin-picking or nail-biting. The study wants to answer two main questions: 1. Does brain stimulation reduce the urge to pick skin or bite nails after those urges are triggered? 2. Does brain stimulation reduce how often people pick their skin or bite their nails? Participants will: * Talk about their skin-picking, nail-biting, and other mental health concerns * Be placed in situations that make them want to pick or bite * Rate how strong their urges are before and after brain stimulation Researchers will compare real brain stimulation to a placebo (a fake version that looks the same but has no effect) to see if the real stimulation works to reduce skin-picking and nail-biting urges and behaviors.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

55 Participants Needed

Emotion Regulation Strategies for Emotional Regulation Issues

Lexington, Kentucky
This trial is testing whether different emotion management techniques help people reduce their negative emotions more effectively. It aims to find out which method works best for improving emotional well-being.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

390 Participants Needed

Tolcapone for Obsessive-Compulsive Disorder

Chicago, Illinois
This trial is testing tolcapone, a medication that may help reduce symptoms of OCD by affecting dopamine levels in the brain. It targets adults with moderate to severe OCD who have significant symptoms. The study also looks at how tolcapone might improve thinking skills and whether genetic differences affect its effectiveness. Tolcapone has been investigated for its potential cognitive benefits in healthy adults.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

85 Participants Needed

Cannabidiol for Obsessive-Compulsive Disorder

Chicago, Illinois
This trial aims to test if Epidiolex can safely and effectively reduce symptoms in adults with obsessive-compulsive and related disorders by calming the brain and reducing anxiety. Epidiolex is a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) that has been previously studied for its potential to be misused.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

4 Participants Needed

Response Inhibition Training for Obsessive-Compulsive Disorder

Milwaukee, Wisconsin
This trial tests a computer-based training program to help people with OCD, hair-pulling, and skin-picking disorders improve their self-control. The training aims to strengthen brain areas that help stop inappropriate actions, potentially reducing symptoms.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

118 Participants Needed

Cognitive Bias Modification for Obsessive-Compulsive Disorder

Milwaukee, Wisconsin
Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., "My mother will get into a car accident, because I thought about it"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

84 Participants Needed

Light Therapy for Obsessive-Compulsive Disorder

St Louis, Missouri
The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\[s\] it aims to answer are: Does light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction. Participants will asked to: 1. Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks 2. Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks 3. Complete a 1-time assessment of sensitivity to light exposure 4. Complete self-report measures of OCD 4 times/day at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:17 - 35

40 Participants Needed

123

Know someone looking for new options? Spread the word

Match to a Trial